Cargando…
Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea
BACKGROUND/AIMS: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse effects (RAEs) of sunitinib have not been investigated. The aim of this study was to determine the incidence and risk factors of RAEs (pro...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932394/ https://www.ncbi.nlm.nih.gov/pubmed/24574832 http://dx.doi.org/10.3904/kjim.2014.29.1.40 |
_version_ | 1782304789835546624 |
---|---|
author | Baek, Seon Ha Kim, Hyunsuk Lee, Jeonghwan Kim, Dong Ki Oh, Kook-Hwan Kim, Yon Su Han, Jin Suk Kim, Tae Min Lee, Se-Hoon Joo, Kwon-Wook |
author_facet | Baek, Seon Ha Kim, Hyunsuk Lee, Jeonghwan Kim, Dong Ki Oh, Kook-Hwan Kim, Yon Su Han, Jin Suk Kim, Tae Min Lee, Se-Hoon Joo, Kwon-Wook |
author_sort | Baek, Seon Ha |
collection | PubMed |
description | BACKGROUND/AIMS: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse effects (RAEs) of sunitinib have not been investigated. The aim of this study was to determine the incidence and risk factors of RAEs (proteinuria [PU] and renal insufficiency [RI]) and to investigate the relationship between PU and antitumor efficacy. METHODS: We performed a retrospective review of medical records of patients who had received sunitinib for more than 3 months. RESULTS: One hundred and fifty-five patients (mean age, 58.7 ± 12.6 years) were enrolled, and the mean baseline creatinine level was 1.24 mg/dL. PU developed in 15 of 111 patients, and preexisting PU was aggravated in six of 111 patients. Only one patient developed typical nephrotic syndrome. Following discontinuation of sunitinib, PU was improved in 12 of 17 patients but persisted in five of 17 patients. RI occurred in 12 of 155 patients, and the maximum creatinine level was 3.31 mg/dL. RI improved in two of 12 patients but persisted in 10 of 12 patients. Risk factors for PU were hypertension, dyslipidemia, and chronic kidney disease. Older age was a risk factor for RI. The median progression-free survival was significantly better for patients who showed PU. CONCLUSIONS: The incidence of RAEs associated with sunitinib was lower than those of previous reports. The severity of RAEs was mild to moderate, and partially reversible after cessation of sunitinib. We suggest that blood pressure, urinalysis, and renal function in patients receiving sunitinib should be monitored closely. |
format | Online Article Text |
id | pubmed-3932394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | The Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-39323942014-02-26 Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea Baek, Seon Ha Kim, Hyunsuk Lee, Jeonghwan Kim, Dong Ki Oh, Kook-Hwan Kim, Yon Su Han, Jin Suk Kim, Tae Min Lee, Se-Hoon Joo, Kwon-Wook Korean J Intern Med Original Article BACKGROUND/AIMS: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse effects (RAEs) of sunitinib have not been investigated. The aim of this study was to determine the incidence and risk factors of RAEs (proteinuria [PU] and renal insufficiency [RI]) and to investigate the relationship between PU and antitumor efficacy. METHODS: We performed a retrospective review of medical records of patients who had received sunitinib for more than 3 months. RESULTS: One hundred and fifty-five patients (mean age, 58.7 ± 12.6 years) were enrolled, and the mean baseline creatinine level was 1.24 mg/dL. PU developed in 15 of 111 patients, and preexisting PU was aggravated in six of 111 patients. Only one patient developed typical nephrotic syndrome. Following discontinuation of sunitinib, PU was improved in 12 of 17 patients but persisted in five of 17 patients. RI occurred in 12 of 155 patients, and the maximum creatinine level was 3.31 mg/dL. RI improved in two of 12 patients but persisted in 10 of 12 patients. Risk factors for PU were hypertension, dyslipidemia, and chronic kidney disease. Older age was a risk factor for RI. The median progression-free survival was significantly better for patients who showed PU. CONCLUSIONS: The incidence of RAEs associated with sunitinib was lower than those of previous reports. The severity of RAEs was mild to moderate, and partially reversible after cessation of sunitinib. We suggest that blood pressure, urinalysis, and renal function in patients receiving sunitinib should be monitored closely. The Korean Association of Internal Medicine 2014-01 2014-01-02 /pmc/articles/PMC3932394/ /pubmed/24574832 http://dx.doi.org/10.3904/kjim.2014.29.1.40 Text en Copyright © 2014 The Korean Association of Internal Medicine http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Baek, Seon Ha Kim, Hyunsuk Lee, Jeonghwan Kim, Dong Ki Oh, Kook-Hwan Kim, Yon Su Han, Jin Suk Kim, Tae Min Lee, Se-Hoon Joo, Kwon-Wook Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea |
title | Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea |
title_full | Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea |
title_fullStr | Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea |
title_full_unstemmed | Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea |
title_short | Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea |
title_sort | renal adverse effects of sunitinib and its clinical significance: a single-center experience in korea |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932394/ https://www.ncbi.nlm.nih.gov/pubmed/24574832 http://dx.doi.org/10.3904/kjim.2014.29.1.40 |
work_keys_str_mv | AT baekseonha renaladverseeffectsofsunitinibanditsclinicalsignificanceasinglecenterexperienceinkorea AT kimhyunsuk renaladverseeffectsofsunitinibanditsclinicalsignificanceasinglecenterexperienceinkorea AT leejeonghwan renaladverseeffectsofsunitinibanditsclinicalsignificanceasinglecenterexperienceinkorea AT kimdongki renaladverseeffectsofsunitinibanditsclinicalsignificanceasinglecenterexperienceinkorea AT ohkookhwan renaladverseeffectsofsunitinibanditsclinicalsignificanceasinglecenterexperienceinkorea AT kimyonsu renaladverseeffectsofsunitinibanditsclinicalsignificanceasinglecenterexperienceinkorea AT hanjinsuk renaladverseeffectsofsunitinibanditsclinicalsignificanceasinglecenterexperienceinkorea AT kimtaemin renaladverseeffectsofsunitinibanditsclinicalsignificanceasinglecenterexperienceinkorea AT leesehoon renaladverseeffectsofsunitinibanditsclinicalsignificanceasinglecenterexperienceinkorea AT jookwonwook renaladverseeffectsofsunitinibanditsclinicalsignificanceasinglecenterexperienceinkorea |